Antipsychotic medication and weight gain: effects of neuromodulation and cognitive training

Not Applicable

• Conditions: Weight gain in patients taking antipsychotic medication for schizophrenia or schizoaffective disorder; Signs and Symptoms

• Registration Number: ISRCTN13280178
• Lead Sponsor: King's College London

Brief Summary

2020 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/32143725 protocol (added 10/03/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-16
• Last Update Posted: 22 August 2022
• Study Completion: 2023-03-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Aged between 18 and 65 years
2. On a stable dose of antipsychotic medication for at least 6 weeks prior to the study enrolment
3. DSM-V diagnosis of schizophrenia or schizoaffective disorder

Exclusion Criteria

1. Significant/unstable medical or psychiatric disorder other than schizophrenia or schizoaffective disorder (e.g. substance dependence)
2. For those taking antidepressant medication - not being on a stable dose for 6 weeks prior to study enrolment
3. Allergies to any of the foods presented in the study
4. Cannot understand verbal English or written information in English
5. History of epileptic seizures, stroke or brain injury
6. Any implanted metal devices in the head
7. Frequent or severe headaches or dizziness
8. Pregnant
9. A tDCS safety questionnaire will also be administered and if considered not safe to deliver tDCS, individuals will subsequently be excluded on this basis

Study & Design

• Study Type: Interventional
• Study Design: Not specified